Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region
DOI:
https://doi.org/10.7175/fe.v21i1.1452Keywords:
Chronic lymphocytic leukemia, Prognostic factors, TP53 deletion, IGHV mutation statusAbstract
BACKGROUND: In the last years genomic and somatic alterations have shown to play a pivotal role in the pathogenesis of chronic lymphocytic leukemia (CLL) and new prognostic factors have been identified accordingly.
AIM: To describe a real-life diagnostic and therapeutic approach to CLL that takes into account the role of genomic and somatic prognostic factors in the risk stratification of developing progressive disease, and treatment decision.
METHODS: This new proposal has been developed and validated by ten key opinion leaders from Tuscany Region during two Expert Meetings. The approach suggested comes from their experience in daily clinical practice and is supported by guidelines recommendations, clinical trials results, and drugs prescribing conditions in Italy.
RESULTS: Beside TP53 deletion or mutated status, the Expert Panel highlighted the importance of the IGHV mutation status characterization, since the diagnosis, in order to identify patients who will have a more aggressive progression. Furthermore, just before starting treatment, to obtain useful prognostic information and indication in the selection of the therapy, they recommend cytogenetic analysis for the detection of del(11q), trisomy 12, del(13q), del(17p), conventional karyotyping of stimulated CLL cells, TP53 sequencing, and molecular genetic analysis to detect IGHV mutation status.
CONCLUSIONS: The Expert Panel recognized the limitations associated with traditional staging systems in identifying patients who will have a more aggressive disease course and predicting response to treatment and suggested a real-life diagnostic and therapeutic approach to CLL to update the current patient management in light of recent advances that have improved understanding of CLL.
References
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In: WHO Classification of Tumours. 4th Edition, Volume 2. IARC: Lyon, 2016
SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. National Cancer Institute. Bethesda, MD. Available at https://seer.cancer.gov/statfacts/html/clyl.html (Last accessed November 2020)
Gruber M, Wu CJ. Evolving understanding of the CLL genome. Semin Hematol 2014; 51: 177-87; https://doi.org/10.1053/j.seminhematol.2014.05.004
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46: 219-34; https://doi.org/10.1182/blood.V46.2.219.219
Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R. Liss; 1987: 253-64
Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
Baliakas P, Mattsson M, Stamatopoulos K, et al. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med 2016; 279: 347-57; https://doi.org/10.1111/joim.12455
Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7; https://doi.org/10.1182/blood.V94.6.1840
Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54; https://doi.org/10.1182/blood.V94.6.1848
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745-60; https://doi.org/10.1182/blood-2017-09-806398
Wierda WG, Byrd JC, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Version 2.2020, October 8, 2019 (Last Accessed October 2019)
International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17: 779-90; https://doi.org/10.1016/S1470-2045(16)30029-8
Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol 2017; 92: 375-80; https://doi.org/10.1002/ajh.24660
Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127: 303-9; https://doi.org/10.1182/blood-2015-09-667675
Burger J, Barr P, Robak T, et al. Ibrutinib For First-Line Treatment Of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll): A 4-Year Experience From The Resonate-2 Study. EHA Learning Center 2018; 214817. Abstract: PF343
Burger JA, Tedeschi A, Barr PM, et al.; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373: 2425-37; https://doi.org/10.1056/NEJMoa1509388
Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 2018; 103: 1502-10; https://doi.org/10.3324/haematol.2018.192328
ESMO guidelines committee Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017. Ann Oncol 2017; 28, 149-52; https://doi.org/10.1093/annonc/mdx242
Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 2017; 3: 16096; https://doi.org/10.1038/nrdp.2016.96
Wendtner CM, Dreger P, Eichhorst B, et al. Chronische Lymphatische Leukämie (CLL). Onkopedia leitlinien, 2019. Available at https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html (last accessed October 2019)
Medina A, Ramírez A, Hernández J, et al. Guía nacional de leucemia linfática crónica y linfoma linfocítico. Grupo Español de Leucemia Linfocítica Crónica (GELLC), 2019. Available at https://www.sehh.es/images/stories/recursos/2019/06/03/Guia-Clinica-LLC-con-Aval.pdf (last accessed October 2019)
Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom 2019; 96: 143-8; https://doi.org/10.1002/cyto.b.21722
Parikh SA, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood 2016; 127: 1752–60; https://doi.org/10.1182/blood-2015-10-620864
Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International Prognostic Score For Early Stage Chronic Lymphocytic Leukemia (IPS A). Hematological Oncology 2019, 37: 81-82; https://doi.org/10.1002/hon.51_2629
Baliakas P, Jeromin S, Iskas M, et al.; ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 2019; 133: 1205-16; https://doi.org/10.1182/blood-2018-09-873083
Imbruvica – Summary of Product Characteristics
Zydelig – Summary of Product Characteristics
Venclyxto – Summary of Product Characteristics
AIFA – Imbruvica monitoring registry. Available at https://www.aifa.gov.it/it/web/guest/registri-e-piani-terapeutici1 (last accessed October 2019)
Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379: 2517-28; https://doi.org/10.1056/NEJMoa1812836
Gozzetti A, Candi V, Fabbri A, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res 2014; 38: 891-5; https://doi.org/10.1016/j.leukres.2014.05.016
Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 2019; 381: 432-43; https://doi.org/10.1056/NEJMoa1817073
Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208-15; https://doi.org/10.1182/blood-2015-06-651125
Eichhorst B, Fink AM, Bahlo J, et al.; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928-42; https://doi.org/10.1016/S1470-2045(16)30051-1
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
